Neridronate Preferentially Suppresses the Urinary Excretion of Peptide-Bound Deoxypyridinoline in Postmenopausal Women

Tobias, Jonathan H; Laversuch, C. V.; Wilson, Nancy; Robins, S. P.

doi:10.1007/s002239900148

Cited by 13 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results are consistent with earlier reports of a much smaller decrease in urine free Dpd, compared with peptide markers NTx and CTx, in response to bisphosphonate therapy, 19,21,24,35 hormone replacement therapy23,24 and calcium supplementation.P Cross-linked telopeptides of type I collagen appear to most sensitively reflect the change in bone resorption in these diverse therapies.…”

Section: Discussionsupporting

confidence: 93%

Clinical Usefulness of Biochemical Resorption Markers in Osteoporosis

Kyd¹,

Vooght²,

Kerkhoff³

et al. 1999

Ann Clin Biochem

View full text Add to dashboard Cite

SUMMARY. We have evaluated three commercial assays for collagen cross-links, two urine assays and a recently developed serum assay, as markers of bone turnover in 30 postmenopausal women with osteoporosis during their first year of treatment with the anti-resorptive drug alendronate.Before treatment, urine free deoxypyridinoline crosslinks (Dpd), urine N-telopeptide crosslinks (NTx) and serum C-telopeptide (CTx) values were within postmenopausal reference ranges. After 3 months' treatment the decrease in NTx and CTx was greater than that ofDpd (-50%, P

show abstract

Section: Discussionsupporting

confidence: 93%

Clinical Usefulness of Biochemical Resorption Markers in Osteoporosis

Kyd¹,

Vooght²,

Kerkhoff³

et al. 1999

Ann Clin Biochem

View full text Add to dashboard Cite

show abstract

“…Alternatively, D-Pyr could re¯ect collagen breakdown in other tissues, but this seems unlikely [1,4,17]. These data further support the hypothesis that the telopeptides are cleaved differently from D-Pyr, accounting for differences in the decrease from baseline with risedronate therapy [15]. After risedronate was discontinued, resorption rates began to increase, but NTx and CTx remained slightly below baseline values at 10 weeks after treatment.…”

Section: Discussionsupporting

confidence: 54%

“…One possible explanation for this is a change in the handling of these degradation products in the kidney [16]. Alternatively inhibition of osteoclastic activity by bisphosphonates could involve not only a change in the absolute rate of bone resorption but also a change in the pattern of collagen breakdown products [15]. One possible explanation for this difference is that the pattern is dependent on the rapidity of bone resorption [1].…”

Section: Discussionmentioning

confidence: 99%

Short-Term Risedronate Treatment in Postmenopausal Women: Effects on Biochemical Markers of Bone Turnover

Raisz

Smith

Trahiotis

et al. 2000

Osteoporosis International

View full text Add to dashboard Cite

The development of new biochemical markers has made it possible to assess the effects of therapeutic agents on bone turnover more rapidly and precisely. In this early phase II study, we analyzed the effects of short-term, high-dose treatment with risedronate, a potent pyridinyl bisphosphonate, on markers of bone resorption and formation. Resorption markers included urinary free deoxypyridinoline (D-Pyr) crosslinks, N-terminal telopeptide (NTx) and C-terminal telopeptide (CTx) type I collagen crosslinks. Bone formation markers included osteocalcin (OC), bone-specific alkaline phosphatase (BSAP) and the C-terminal peptide of type I procollagen (PICP). All three resorption markers showed rapid, significant (p<0.05) decreases from baseline following daily administration of 30 mg risedronate for 2 weeks. The mean decreases at 2 weeks were 28% for D-Pyr, 61% for NTx and 73% for CTx, respectively. Over the next 10 weeks after treatment, D-Pyr approached baseline while NTx and CTx remained well below baseline values. The markers of bone formation showed little change during therapy but decreased significantly at 4-10 weeks after therapy - an expected outcome of bisphosphonate therapy. Moreover, there was a significant correlation between the early effects on bone resorption markers and the delayed effects on formation markers. This study demonstrates that the approved dose of risedonate (30 mg/day) for Paget's disease is effective at decreasing bone turnover after 2 weeks of treatment, as observed by the sensitive response of bone turnover markers.

show abstract

“…Garnero et al [12] reported large changes in the peptidebound crosslinks (e.g., NTX and CTX), smaller changes in the total PYD and DPD and no change in the free PYD and DPD in response to bisphosponate therapy in patient with Paget's disease and osteoporotic postmenopausal women, but similar changes in excretion of free, total and peptide-bound PYD and DPD following hormone replacement therapy in postmenopausal women. According to some studies [13,14,15,17], but not others [16], it has been proposed that when going from a low to a high bone turnover state (such as the postmenopausal period), excretion of free PYD and DPD is increased less than the excretion of total PYD and DPD and peptide-bound crosslinks.…”

Section: Discussionmentioning

confidence: 99%

“…These assays could represent a valuable alternative to the more difficult HPLC technique [5,[9][10][11]. Since the metabolic origins of the urinary free and bound crosslinks are unknown, it is not certain that the determination of free, peptide-bound or total pyridinium crosslink excretion will provide similar information in different clinical situations [12][13][14][15][16][17].…”

Section: Introductionmentioning

confidence: 99%

Effects of Age, Menopause and Osteoporosis on Free, Peptide-Bound and Total Pyridinium Crosslink Excretion

Campo

González-Casaús

Aguado

et al. 1999

Osteoporosis International

View full text Add to dashboard Cite

We evaluated urinary excretion of free pyridinoline (PYD)-deoxypyridinoline (DPD) by an enzymelinked immunosorbent assay (ELISA) method, free and total PYD by high-performance liquid chromatography (HPLC), free DPD by ELISA, chemiluminiscent immunoassay (CLEIA) and HPLC, total DPD by HPLC, and N-telopeptides (NTX) and C-telopeptides (CTX) by ELISA in 234 women distributed into three groups: 43 healthy young women (aged 26.2 +/- 2.5 years), 56 control postmenopausal women (aged 55.9 +/- 4.5 years) and 133 untreated osteoporotic women (aged 55.1 +/- 4.0 years). The control postmenopausal women had increased values of all markers considered, except NTX, compared with healthy young women. The osteoporotic postmenopausal women had significantly increased values compared with control postmenopausal women for free DPD by HPLC and free DPD by ELISA or CLEIA. HPLC, ELISA and CLEIA showed adequate correlation to measure free PYD and DPD. Control postmenopausal women had significantly decreased values of the fraction of free PYD and DPD (48.4% and 32.0%, respectively), as did the osteoporotic postmenopausal women (48.0% and 46.1%), compared with healthy young women (55.3% and 57.0%). We found a significant negative correlation comparing age with fraction of free PYD and DPD, but a positive correlation with total PYD and DPD, considering or not the osteoporotic postmenopausal women. T-score and Z-score values derived from healthy young women and control postmenopausal women for PYD, DPD, NTX and CTX measured by immunoassays were calculated to detect changes in bone turnover, DPD by ELISA or CLEIA showing the highest Z-score. The sensitivity and specificity of the different assays were evaluated using a receiver operating characteristic (ROC) curve. With a specificity of 90% the sensitivity of the markers considered was low (from 33% for DPD by CLEIA to 11% for PYD-DPD by ELISA), but increased considerably with a specificity of 75%. In conclusion, urinary pyridinium crosslink derivatives increase with age and after the menopause, and rise slightly in women with osteoporosis, there being a negative correlation among age and the fraction of free PYD and DPD of the total urinary excretion. Among the resorption markers most often available in clinical laboratories, free DPD by ELISA or CLEIA was the best at discriminating osteoporotic postmenopausal women from aged-matched control postmenopausal women.

show abstract

Neridronate Preferentially Suppresses the Urinary Excretion of Peptide-Bound Deoxypyridinoline in Postmenopausal Women

Cited by 13 publications

References 0 publications

Clinical Usefulness of Biochemical Resorption Markers in Osteoporosis

Clinical Usefulness of Biochemical Resorption Markers in Osteoporosis

Short-Term Risedronate Treatment in Postmenopausal Women: Effects on Biochemical Markers of Bone Turnover

Effects of Age, Menopause and Osteoporosis on Free, Peptide-Bound and Total Pyridinium Crosslink Excretion

Contact Info

Product

Resources

About